I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Temsirolimus is used as a rapamycin derivative with anti-cancer activity that inhibits mTOR. Temsirolimus is an antiproliferative and antiangiogenic, the first-in-class mTOR inhibitor approved for the treatment of patients with advanced poor prognosis renal cell carcinoma.
Joseph Boni.; Cathie Leister.; Jaime Burns.; Maria Cincotta.; Bruce Hug.; Laurence Moore. Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450-Inducing Medications1.The Journal of Clinical Pharmacology.2007, (11), 1430-1439.